Cost-effectiveness of a text message programme for the prevention of recurrent cardiovascular events

被引:43
|
作者
Burn, Edward [1 ]
Nghiem, Son [1 ]
Jan, Stephen [2 ]
Redfern, Julie [2 ]
Rodgers, Anthony [2 ]
Thiagalingam, Aravinda [3 ,4 ]
Graves, Nicholas [1 ]
Chow, Clara K. [2 ,3 ,4 ]
机构
[1] Queensland Univ Technol, Brisbane, Qld, Australia
[2] Univ Sydney, George Inst Global Hlth, Sydney Med Sch, Sydney, NSW, Australia
[3] Westmead Hosp, Dept Cardiol, Sydney, NSW, Australia
[4] Univ Sydney, Westmead Clin Sch, Sydney, NSW, Australia
基金
澳大利亚国家健康与医学研究理事会; 英国医学研究理事会;
关键词
CORONARY-HEART-DISEASE; RISK-FACTOR; LIFE-STYLE; SMOKING; HEALTH; MODEL; INTERVENTIONS; INDIVIDUALS; UNCERTAINTY; STROKE;
D O I
10.1136/heartjnl-2016-310195
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To estimate the cost-effectiveness of Tobacco, Exercise and Diet Messages (TEXT ME), a text message-based intervention that provides advice, motivation, information and support to improve health-related behaviours. Methods A lifetime Markov model was used to estimate major vascular events (myocardial infarctions and strokes) avoided, quality-adjusted life years (QALYs) gained, costs to the health system and the incremental cost per QALY gained. The model was informed by data from a randomised controlled trial of TEXT ME, with evidence from systematic reviews and meta-analyses used to estimate the effects of changes in risk factors on the risk of major vascular events. Expected costs and health outcomes were estimated with uncertainty surrounding these characterised using probabilistic sensitivity analysis and a number of scenario analyses. Results For a target population of 50 000 patients with documented coronary heart disease, the intervention is expected to lead to 563 fewer myocardial infarctions, 361 fewer strokes and 1143 additional QALYs. TEXT ME is expected to lead to an overall saving of $ 10.56 million for the health system over the patients' lifetimes. The intervention can therefore be considered cost-saving and health-improving. Neither parameter nor structural uncertainty had a significant impact on the conclusion that TEXT ME is cost-effective. Conclusions The provision of TEXT ME is predicted to lead to better health outcomes and an overall saving in costs for the health system.
引用
收藏
页码:923 / U57
页数:8
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular events among patients with type 2 diabetes in China
    Jiang, Minghuan
    Li, Pengchao
    You, Joyce Hoi-sze
    Zheng, Xinglong
    Deng, Jizhao
    Zhao, Mingyue
    Feng, Liuxin
    Fang, Yu
    PLOS ONE, 2019, 14 (12):
  • [42] Influenza vaccination in acute coronary syndromes patients in Thailand:the cost-effectiveness analysis of the prevention for cardiovascular events and pneumonia
    Apirak Sribhutorn
    Arintaya Phrommintikul
    Wanwarang Wongcharoen
    Usa Chaikledkaew
    Suntara Eakanunkul
    Apichard Sukonthasarn
    Journal of Geriatric Cardiology, 2018, 15 (06) : 413 - 421
  • [43] Cost-effectiveness of stroke prevention
    Ebrahim, S
    BRITISH MEDICAL BULLETIN, 2000, 56 (02) : 557 - 570
  • [44] Cost-Effectiveness of Statins for Primary Cardiovascular Prevention in Chronic Kidney Disease
    Erickson, Kevin F.
    Japa, Sohan
    Owens, Douglas K.
    Chertow, Glenn M.
    Garber, Alan M.
    Goldhaber-Fiebert, Jeremy D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (12) : 1250 - 1258
  • [45] Cost-effectiveness of icosapent ethyl for primary and secondary cardiovascular prevention in the UK
    Michaeli, D. T.
    Michaeli, J. C.
    Boch, T.
    Michaeli, T.
    EUROPEAN HEART JOURNAL, 2022, 43 : 2845 - 2845
  • [46] Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease
    Ferket, Bart S.
    Hunink, M. G. Myriam
    Khanji, Mohammed
    Agarwal, Isha
    Fleischmann, Kirsten E.
    Petersen, Steffen E.
    HEART, 2017, 103 (07) : 491 - 499
  • [47] Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study
    Linda J Cobiac
    Anne Magnus
    Jan J Barendregt
    Rob Carter
    Theo Vos
    BMC Public Health, 12
  • [48] Smoking cessation for primary prevention of cardiovascular disease: A cost-effectiveness analysis
    Kinderen, AJD
    Oh, F
    De Laet, C
    VALUE IN HEALTH, 2004, 7 (06) : 692 - 693
  • [49] Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
    Michaeli, Daniel Tobias
    Michaeli, Julia Caroline
    Boch, Tobias
    Michaeli, Thomas
    CARDIOVASCULAR DRUGS AND THERAPY, 2023, 37 (04) : 683 - 694
  • [50] COST-EFFECTIVENESS OF EICOSAPENTAENOIC ACID (EPA) ON PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE
    Kodera, S.
    Kiyosue, A.
    Ando, J.
    Komuro, I
    VALUE IN HEALTH, 2017, 20 (09) : A614 - A614